Protein biomarkers in plasma: revealing biological insights into the tumor microenvironment
Thursday 20th May 2021
08:00 PDT; 11:00 EDT; 16:00 BST; 17:00 CEST
Immunotherapy has become a pillar of cancer treatment, although the majority of patients treated with immune checkpoint blockade (ICB) do not generate durable treatment responses, acquire resistance or are limited by treatment-related toxicities. There is a critical need to identify early non-invasive biomarkers of response and to improve our understanding of the mechanisms that drive treatment failure. Due to the complex relationship between the host immune response and biology of tumors, multiomic approaches are often required to understand the molecular basis for non-response to ICB.
Blood plasma proteomic analyses allows longitudinal assessment of the immune system activation and real-time monitoring of the treatment dynamics. Leveraging proteins in circulation with single-cell RNA-sequencing data of tumor biopsies can generate further biological insight into the tumor-intrinsic response to immunotherapy.
In this webinar, two respected scientists at Massachusetts General Hospital, Genevieve Boland and Arnav Mehta will tell us how an extensive plasma proteomic analysis revealed biological insights about the tumor microenvironment in melanoma patients after immune checkpoint blockade and helped them to identify composite biomarkers to better predict sensitivity and response to immunotherapy.
Attendees will learn:
- An understanding of how to analyze large proteomic datasets and the possible limitations involved
- How plasma proteomics can be used for monitoring the immune response following immune checkpoint blockade
- How plasma proteomics are used to gain insights into biological pathways underlying response and non-response to immune checkpoint blockade
- Understand the value of combining plasma proteomics and single-cell RNA-sequencing data from tumor biopsies to identify the cellular and molecular basis of immune checkpoint response.